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Abstract
Background: Toxicity is rarely considered in the differential diagnosis of conjunctivitis, but we present here a new
form of toxic conjunctivitis with unusual clinical features. Between 2010 and 2013, a new clinical presentation of
chronic conjunctivitis unresponsive to normal treatment was noted within a Primary Care Ophthalmology Service.
Methods: Retrospective review of case records and histopathology results.
Results: A total of 55 adult patients, all females, presented with epiphora and stickiness. They did not complain of
itch and had had symptoms for an average of 9 months. Clinical examination showed bilateral moderate to severe
upper and lower tarsal conjunctival papillary reaction, without corneal or eyelid changes and mild bulbar
conjunctival hyperaemia in a third of cases. Biopsies were taken in 15 cases to exclude an atypical infection or
lymphoma. Histologically, there was a variable superficial stromal lymphocytic infiltrate, involving the epithelium in
more severe cases. The majority of the cells were CD3 positive T-lymphocytes and follicle formation was not noted.
The clinical history in all cases included prolonged use of eye make- up and other facial cosmetic products. Clinical
symptoms of epiphora settled with topical steroid drops, but the clinical signs of chronic tarsal inflammation
persisted until withdrawal of the facial wipes thought to contain the inciting agent, though the exact nature of this
remains unclear.
Conclusion: The presentation, appearances, histological features are consistent with a contact allergen-driven
chronic conjunctivitis. Steroid treatment provided good relief of symptoms and patients were advised to avoid
potential contact allergens. Management remains difficult. Further research into contact allergies of mucous
membranes and identification of its allergens is required.
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Background
Many forms of chronic conjunctivitis are recognised. The
commonest type is probably chronic allergic conjunctivitis
manifesting as itchy red eyes with thickened eyelid margins
and associated periorbital dermatitis, usually associated
with atopy [1, 2]. Itch is always a major feature of chronic
allergic conjunctivitis. Other forms of chronic conjunctivitis
include meibomian gland disease blepharo-conjunctivitis,
contact lens-related giant papillary conjunctivitis, floppy
eyelid syndrome, post chemotherapy conjunctivitis, cicatris-
ing conjunctivitis, periocular dermatitis, giant fornix syn-
drome, and chlamydial conjunctivitis [3]. Toxicity is rarely
considered, and there are relatively few publications in the
field, but chronic toxic conjunctivitis has been described
presenting with a clinical picture of watery discharge,
conjunctival papillary initial reaction, follicular subsequent
reaction, often eyelid dermatitis and inferior punctal ero-
sions [4–6].
We have recently noted increased referral rates to our
Primary Care Ophthalmology (PCO) service of patients
with an atypical presentation with epiphora as the primary
symptom. Other common causes of epiphora include ac-
tual nasolacrimal duct obstruction and functional nasola-
crimal duct obstruction, but we have not noted any
increase in the numbers of patients presenting with either
condition. Between 2010 and 2013, one of us (NC) noted
this new clinical presentation of chronic conjunctivitis,
and in 2013, this became epidemic with 17 new cases
referred in 2013 and 29 in the first 8 months of 2014. This
paper presents a retrospective review of the clinical fea-
tures of a series of 55 cases of this new form of conjunctiv-
itis, to September 2014.* Correspondence: i.a.cree@warwick.ac.uk
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Methods
Retrospective review of standard clinical and laboratory
investigations was conducted in a series of 55 patients
with a newly recognised form of conjunctivitis. Our review
conforms to the tenets of the Declaration of Helsinki. Due
to its retrospective nature, UK Health Research Authority
Ethics Committee approval was not required. Consent for
publication is not required as long as the patients are not
identifiable. The patients undergoing biopsy were fully in-
formed of the risks and benefits involved and gave written
informed consent for the procedure, including use of ocu-
lar photographs, tissue, and related data for research and
teaching.
Clinical management
Standard slit lamp examination with tarsal conjunctival
digital photography (Topcon 3D OCT 2000) was per-
formed to document conjunctival changes. In the early
cases some patients underwent sac washout to determine
nasolacrimal duct patency, but this test was rapidly con-
sidered irrelevant since the primary site of the problem is
the conjunctiva and not the punctum or nasolacrimal
duct. The only effective treatment was topical steroid
drops. Consequently careful follow up was required par-
ticularly to monitor intraocular pressure. Resolution of the
condition was considered when the patient had been off
topical steroids for 2 months, with no epiphora symptom
and normal tarsal conjunctival appearances.
Microbiology
In four patients swabs were sent for chlamydial testing
(BD Viper, Becton Dickinson, Oxford, England), all of
which were negative. No swabs were sent for bacterio-
logical analysis.
Biopsy and histopathology
Since the course of the condition was prolonged and
aetiology uncertain, fifteen newly presenting consecutive
patients consented to conjunctival biopsy. Punch biop-
sies (1 mm) were taken from the tarsal conjunctiva in 15
cases. These were fixed in neutral buffered formalin (4 %
formaldehyde), processed and embedded in paraffin wax.
Sections cut at 4 μm were stained with haematoxylin
and eosin, and examined by direct microscopy. Immuno-
histochemistry for CD3 (a T-lymphocyte marker) and
CD20 (a B-lymphocyte marker) was performed to
phenotype lymphocytes within the infiltrate.
Allergen sensitivity testing
Skin patch-testing with IQ Ultra (Chemotechnique
Diagnostics, Sweden) was performed in 43.6 % (24/55)
cases by a dermatologist, according to manufacturer’s
instructions. All patients were tested with the British
standard battery (British Society for Cutaneous Allergy)
including EDTA and benzalkonium chloride. Results
were read on day 2 and day 4 following initial applica-
tion. Erythema with infiltration, papules or vesicles on
the skin were considered positive results. Their clinical
relevance was interpreted in association with the his-
tory of present complaints, improvement of symptoms
by withdrawal of a suspected contact allergen or previ-
ous reactions on exposure to contact allergens. Ques-
tionnaires and electronic hospital files were used in
order to obtain information on a personal history of
atopy (at least one of the following conditions should
be present in one patient: asthma, eczema or hayfever),
occupational exposure to contact allergens, the applica-




A total of 55 patients were included in this retrospective
case series. All were adult females with a median age of
44 years (range 17–72) presenting during the period
2010–2014 as referrals from primary care practitioners in
whom standard treatments for epiphora and conjunctivitis
had already been undertaken and had not been successful.
The clinical findings are summarised in Additional file 1:
Table S1. Epiphora was the commonest presenting symp-
tom. Associated symptoms included stickiness, and itch
featured in only 1 patient. None wore contact lenses and
all had had the condition for at least a month (mean
9 months, range 1 – 36 months). All patients had previ-
ously used cosmetics on a daily basis.
The cardinal clinical sign was a bilateral moderate to
severe upper and lower tarsal conjunctival papillary reac-
tion (Fig. 1). In a third of cases there was a mild bulbar
conjunctival hyperaemia, but in most cases the bulbar
conjunctiva was normal. Important negative signs in-
cluded a lack of corneal changes, eyelid dermatitis or lid
margin thickening. Differential diagnoses were excluded
by history, examination or lack of response to treatment
(including previous treatment prior to referral).
Microbiology
In 7.1 % (4/55) patients, standard microbiology excluded
chlamydial infection. Although not clinically a follicular
conjunctivitis, all patients were treated empirically with
a trial of 1 g azithromycin after counselling, with no re-
sponse in either symptoms or signs.
Histopathology
H&E slides showed conjunctival tissue with mild (n = 3),
moderate (n = 5), or severe (n = 4) superficial stromal
chronic inflammation, involving the epithelium in all se-
vere and moderate cases. Inflammation could not be
graded in 3 cases with insufficient material for this to be
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assessed. The inflammation was predominantly lympho-
cytic with a striking lack of lymphoid follicle formation
(Fig. 2). Goblet cell numbers were variable, with both in-
creased and decreased numbers noted. On immunohis-
tochemistry, the majority of cells were clearly of CD3
positive T-lymphocytes, with variable but lower numbers
of CD20 positive B-lymphocytes (Fig. 2). There was no
evidence of lymphoma, cicatricial pemphigoid, vernal
conjunctivitis, and other infectious causes. There were
few neutrophils, eosinophils or macrophages and no
granulomas were observed. No basal epithelial apoptosis
were noted, excluding a lichenoid reaction. The appear-
ances were thought to be consistent with contact allergy.
Allergen sensitivity testing
In total, 72 % (40/55) were invited for patch-testing,
40 % (16/40) did not attend their appointment. Amongst
all patients patch-tested, 45.8 % (11/24) were sensitised
to Nickel, 4.1 % (1/24) to methylisothaizolinone (MI)
(0.2 % strength), 4.1 % (1/24) to fragrance mix 1 and bal-
sam of Peru, 4.1 % (1/24) to PPD (p-Paraphenylendia-
mine) and 4.1 % (1/24) to Potassium dichromate.
Only 9 % (1/11) of Nickel positive patients confirmed a
past medical history of skin reactions to Nickel containing
custom jewellery, no one else sensitised on patch-testing
to one or more contact allergens had a relevant past
medical history of contact dermatitis. 16.6 % (4/24) had a
personal history of atopy. No one was exposed to potential
contact allergens at work or during leisure time.
Response to treatment
The first 15 patients in this series were given olopatadine
(Opatanol) anti-histamine and nedocromil (Rapitil) for sev-
eral months, with no response. Clinical symptoms of epiph-
ora typically settled within a week or two of starting topical
steroid drops, either dexamethasone 0.1 % (Maxidex) or
prednisolone 0.5 % (Predsol), but the clinical signs of
chronic tarsal inflammation usually remained for many
months despite continuous topical steroid use. As the fre-
quency of the topical steroid drops was reduced over
months and the strength was reduced to fluorometholone,
the symptom of epiphora and the signs of chronic tarsal in-
flammation tended to recur. This pattern of response to
topical steroid and recurrence on stopping steroid persisted
until the summer of 2014 when a contact sensitivity re-
sponse was suspected. At this point all patients were ad-
vised to refrain (or at least be minimalist) about application
of facial products and to refrain from using facial wipes.
Since this approach was taken in 83.6 % (46/55) cases it is
known that the condition is completely resolved, with all
patients in this series discharged by April 2015. One of this
series of patients developed raised intraocular pressure
Fig. 1 Clinical appearances of the eye in two representative cases, showing the superior and inferior tarsal conjunctival appearances in two
patients. a Lower lid, b upper lid from one patient, and c lower lid and d upper lid from another. Both show typical papillary appearances with
some hyperaemia
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requiring cessation of steroid treatment. The reasons for
loss to follow up, 16.3 % (9/55), is unknown. As access to
the PCO service by self-referral is relatively straight for-
ward, one reason for non-attendance might be complete
resolution of symptoms.
In the initial stages, 8 patients were referred into the
local Hospital Eye Service. Some of these patients subse-
quently returned to the Primary Care Ophthalmology
service for continuity of care. Additional file 2: Table S2
describes the outcomes for these patients.
Discussion
We describe here a rapid rise in incidence of a new form of
chronic conjunctivitis (Fig. 3), which we believe to be a
form of contact conjunctivitis related to changes in the con-
stituents of peri-ocular cosmetics or the facial wipes used
to remove them. Cosmetics have been previously known to
cause problems in the eye [7] and some toxicity testing in
the eye is performed in most products on the market, using
the Draize eye test and animal-free alternatives [8, 9]. This
is usually aimed at excluding corneal toxicity, but in this
instance it appears that effects on the conjunctiva have
produced a clinically well-defined syndrome.
While this condition is likely to be present in the patient
population presenting to hospital ophthalmology depart-
ments, it may be missed amongst the multitude of other
cases. The Primary Care Ophthalmology service, staffed by
a single practitioner general ophthalmologist, sees nearly all
new patients with epiphora for the population of Rugby
(n = 100,000) as well as patients from other nearby areas.
Assuming a UK population of 63 million and that this new
disease presentation is similarly represented through the
UK, extrapolation suggests that up to 13,000 patients may
have presented with this condition within the UK in 2014.
This form of conjunctivitis is of particular concern
since the condition requires follow up and topical ster-
oid treatment for months or even years unless the cor-
rect management is undertaken. The only effective
treatment we have identified to date is topical steroid
and avoidance of periocular preparations and facial
wipes. Cataract formation is a risk when steroids are
used for prolonged periods, and in most cases, the ster-
oid was reduced from standard strength (eg dexametha-
sone 0.1 %) to weakest strength (eg Fluorometholone,
FML) within 3 months. Being on a reducing dose of
FML for 6–12 months probably does not have a high
cataract progression risk. However, it is of concern that
many of these patients are at risk of remaining on top-
ical steroids for long periods to control their symptoms
unless they are prepared to cease using all facial prod-
ucts and use of facial wipes and eliminate the cause.
In December 2013, there was extensive UK media cover-
age about an epidemic of dermatological problems being
caused by the chemical methylisothaizolinone (MI) and
methylchlorisothiazolinone (MCI), both collectively also
known as Kathon, which are used to increase the shelf life
of cosmetics, lotions, soaps, shampoos, other body products
and skin cleansers [10, 11]. These were initially introduced
as cosmetic preservatives in 2006 and since then have be-
come widely used. Since their introduction unprecedented
number of contact allergies and contact dermatitis
have been reported. In the US the Environmental
Fig. 2 Histological appearance of the inflammatory infiltrate in the
conjunctiva. a H&E showing involvement of the conjunctival stroma
and epithelium by lymphocytic inflammation. b CD3 stained section
showing that the infiltrate consists mainly of T lymphocytes. c CD20
stained consecutive section showing that there are also significant
numbers of B lymphocytes
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Working Groups Cosmetic Database considers MI to
be a moderate health hazard because it is a chemical
irritant that can affect the skin, eyes or lungs. MI has
been banned in Canada, but is still popularly used in
the US. MI has been considered as “contact allergen
for 2013” by the American Contact Dermatitis Society.
The European Commission Scientific Committee on
Consumer safety (http://ec.europa.eu/health/scienti-
fic_committees/consumer_safety/docs/sccs_o_145.pdf )
considers MI to be a strong sensitiser with a potency
category of “extreme” and that the dramatic rise in rates of
contact allergy to MI, as detected by diagnostic patch tests,
is unprecedented in Europe. Due to the rising number of
cases in 2014 and an awareness of potential problems with
Kathon, patients were advised to try and avoid products
containing Kathon, though the problem could certainly not
be attributed to this agent. Skin patch testing was under-
taken to identify possible causes, but the results did not
support our suspicion. This might be simply due to failure
in identifying the responsible contact allergen, which is
known to be difficult. Random testing is not recommended
as it creates a high rate of false positives [12] and atopic
disease is associated with a higher risk of contact allergy
[13]. In those patients who attended patch testing, with-
drawal of suspected contact allergens did not show a clear
trend of improvement of symptoms, likewise continuous
exposure did not coincide with persistence of symptoms.
Sensitisation of patients to contact allergens on patch-
testing did not seem to be linked to true contact dermatitis
which is again in keeping with data on false positivity in the
literature [14]. The high percentage of nickel sensitisation
in our patients can be explained by our cohort being
exclusively female [13]. The mechanisms of nickel
hypersensitivity have been studied in detail, and are the re-
sult of haptenisation of proteins following skin exposure
leading to the activation of hapten-specific T-lymphocytes
[15]. The fact that women with positive test results did not
have a history of contact dermatitis and equally, current
symptoms of tarsal conjunctivitis do not seem to be associ-
ated with the sensitisation shown on testing, reflects the
low sensitivity and specificity of 70 % of patch testing [14].
Cosmetic products such as eye shadows are known to
contain nickel particles in variable concentrations.
Brown and green colours contain the highest nickel
levels and lead potentially to eye lid dermatitis and allergic
contact conjunctivitis. Only one of our patients had a his-
tory of contact dermatitis to custom jewellery, a positive
test to nickel but no symptoms on current continuous use
of brown and green eye shadow. Overall, the skin testing
results have to be interpreted with caution as the data are
incomplete. Half of the patient cohort failed to attend
testing and not every attendee completed a questionnaire.
The suitability of skin patch-testing for diagnosing
contact dermatitis in mucous membranes is contentious.
To our knowledge, no data are available on sensitisation
thresholds of conjunctiva compared to the skin but there
is literature raising awareness of different sensitisation
thresholds of skin in different parts of the body such the
back compared to the eyelids due to the variable thick-
ness of the skin and the impact on penetration of con-
tact allergens. This requires different concentrations of
the contact allergen in order to achieve the same reac-
tion [16]. The eye lashes and the tear film act as mech-
anical barrier to ocular exposure, but once these barriers
are overcome, the highly vascularised conjunctiva facilitates
access for contact allergens. One study by Villarreal reports
Fig. 3 Increasing numbers and population derivation of chronic tarsal conjunctivitis over five years
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the sensitivity of patch testing for allergic type 4 conjunctiv-
itis as 74 % [17], which is similar to that for allergic contact
dermatitis [14]. Its negative predictive value was low at
41 %. In 24 % of patients an additional conjunctival
challenge had to be performed to diagnose an underlying
contact allergy [17]. Unfortunately, in our series, the derma-
tology department undertaking patch-testing for this study
was unable to perform conjunctival challenge tests.
Finally, the tarsal conjunctivitis could be an irritant
conjunctivitis rather than a true type 4 mediated allergic
conjunctivitis and therefore patch-testing failed to identify
the culprit. The irritant threshold is proven to be different
in skin and mucous membranes and recovery will be more
difficult as withdrawal of the trigger does not result in rapid
improvement as in contact allergic reactions. For instance,
the irritant threshold for kathon on mucous membranes is
lower than on the skin causing corrosion [18].
Our management (Table 1) was based on topical ocular
steroid treatment with removal of facial products, including
all facial wipes/make-up remover wipes, cosmetics, and
moisturising products. The key attribute of the patients
who have been discharged was a willingness to reduce sig-
nificantly the products that they were putting on and
around the eyelids. Some patients stopped everything, while
others restricted application of facial products to 2–3 nights
out a month. Clearly, it is important to establish the exact
aetiology of this type of conjunctivitis.
In some patients, the onset of symptoms appeared to co-
incide with the use of a supermarket brand of facial wipes.
The brand of facial wipes concerned did not contain MI or
MCI. On further questioning of the female patients as they
have come back for review, at least 17 patients (c 30 % of
cases presently under active review) were found to have
used or be using these branded facial wipes. Those that
were using facial wipes observed resolution of symptoms
on ceasing using the facial wipes, in conjunction with
several months of topical steroid drops. The vendor did
change the formulation of their wipes from September
2015, and no new cases have been seen since December
2015. The main change in formulation was the supplier
changing preservatives (to a paraben and phenoxyethanol
free recipe). While there do not appear to be any published
studies linking phenoxyethanel with conjunctivitis, para-
bens in eye-drops have been noted to cause contact derma-
titis [19], and it is possible that this is the causative agent
responsible for the condition we have observed.
Conclusion
Chronic tarsal conjunctivitis is an unusual form of con-
junctivitis that appears to be related to the use of a sin-
gle brand of facial wipes, and may be toxic or contact-
allergen driven by paraben used as a preservative. It is
important that ophthalmologists recognise this new con-
dition and, in conjunction with the patient, consider the
management strategy detailed in this paper.
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Table 1 Management strategy for chronic tarsal conjunctivitis
1) Investigation by ophthalmology, including examination, swabs for
chlamydia and biopsy (if necessary) to exclude other conditions.
2) Initiate treatment with a reasonable strength of topical steroid.
Despite a rapid response of symptoms, continue on these drops for
at least one month. Then slowly tail off over at least three months,
titrating clinical features of tarsal conjunctival inflammation with
strength and frequency of drops used. Don’t stop/tail off too quickly
or symptoms and signs will recur.
3) Reduce as far as possible all facial products. This applies to facial
wipes/make-up remover wipes/cosmetics/moisturising products.
4) On some occasions, the strength of topical steroid may have to be
increased to control the symptoms when tarsal conjunctival inflammatory
signs remain. Such resistance to treatment is to be expected if the
underlying irritant is still being applied on and around the eyelids.
5) Elimination of the use of all products to the skin of eyes and eyelids
is the best advice, but few women are prepared to consider this.
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